Data / Form D filings / Dracen Pharmaceuticals, Inc.
Dracen Pharmaceuticals, Inc.: Form D filings
Dracen Pharmaceuticals, Inc., a biotechnology company in San Diego, CA, filed 3 Form D notices with the SEC between 2018 and 2023. The latest, on August 10, 2023, reports $2.3 million sold of a $2.8 million offering to 6 investors.
SpecStream is the live web data engine for teams and agents. It reads every Form D on SEC EDGAR the day it is filed, and this page is that reading. Ask for your own cut (a state, an industry, a size) and new filings arrive in your sheet, CRM, Slack or agent as they land.
Company details from the filing
- Address
- 9276 Scranton Road #200, San Diego, CA, 92121
- Phone
- (410) 659-2777
- Industry
- Biotechnology
- Entity type
- Corporation
- Incorporated in
- Delaware
- Revenue range
- Decline to Disclose
- Exemptions claimed
- Rule 506(b)
- SEC identifier (CIK)
- 1728955
Form D filings
| Filed | Type | Offering | Sold | Remaining | Investors | First sale | Filing |
|---|---|---|---|---|---|---|---|
| Aug 10, 2023 | New notice | $2,785,000 | $2,285,000 | $500,000 | 6 | Jun 11, 2023 | sec.gov |
| Nov 10, 2021 | New notice | $17,046,698 | $8,584,398 | $8,462,300 | 8 | Nov 1, 2021 | sec.gov |
| Jan 24, 2018 | New notice | $40,489,688 | $8,488,896 | $32,000,792 | 9 | Jan 11, 2018 | sec.gov |
Executive officers and directors named in the filing
| Name | Role | Note in the filing |
|---|---|---|
| Asher M. Rubin | Executive Officer | |
| Drew M. Pardoll, M.D., Ph.D. | Director | |
| Dennis M. Bilski | Executive Officer | |
| Jonathan M. Leff | Director |
Other biotechnology companies in California that filed recently
- Trellis Bioscience, Inc. $9.1 million · Oct 29, 2026
- BigHat Biosciences, Inc. $75.1 million · Oct 26, 2026
- Theravie Pharma, Inc. $750,000 · Oct 19, 2026
- Adela, Inc. $12 million · Oct 19, 2026
- Estuary Biotherapeutics, Inc. $40.7 million · Oct 16, 2026
- Renue Life Sciences, Inc. $250,000 · Oct 14, 2026
Every Form D from the week of Aug 7, 2023 · All recent filings in California · All recent Biotechnology filings
Read from SEC EDGAR. Amount sold is what Dracen Pharmaceuticals, Inc. reported on the day it filed; on an offering that is still open, a later amendment can raise it. Free to reuse with credit to SpecStream under CC BY 4.0.